MA34263B1 - Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs) - Google Patents

Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)

Info

Publication number
MA34263B1
MA34263B1 MA35412A MA35412A MA34263B1 MA 34263 B1 MA34263 B1 MA 34263B1 MA 35412 A MA35412 A MA 35412A MA 35412 A MA35412 A MA 35412A MA 34263 B1 MA34263 B1 MA 34263B1
Authority
MA
Morocco
Prior art keywords
fxs
syndrome
markers useful
prediction markers
treating fragile
Prior art date
Application number
MA35412A
Other languages
English (en)
Inventor
Baltazar Gomez-Mancilla
Yunsheng He
Donald Johns
Joanne Meyer
Charles Paulding
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44121075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34263(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34263B1 publication Critical patent/MA34263B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne l'utilisation de biomarqueurs pour déterminer la sensibilité d'un individu atteint du syndrome de l'X fragile (FXS) au traitement par un antagoniste de mGluR5.
MA35412A 2010-04-30 2011-04-28 Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs) MA34263B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33029910P 2010-04-30 2010-04-30
US37919710P 2010-09-01 2010-09-01
PCT/US2011/034244 WO2011137206A1 (fr) 2010-04-30 2011-04-28 Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)

Publications (1)

Publication Number Publication Date
MA34263B1 true MA34263B1 (fr) 2013-05-02

Family

ID=44121075

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35412A MA34263B1 (fr) 2010-04-30 2011-04-28 Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)

Country Status (21)

Country Link
US (1) US20130052644A1 (fr)
EP (1) EP2563934A1 (fr)
JP (1) JP2013524840A (fr)
KR (1) KR20130100906A (fr)
CN (1) CN102869791A (fr)
AU (1) AU2011245372A1 (fr)
BR (1) BR112012027816A2 (fr)
CA (1) CA2797854A1 (fr)
CL (1) CL2012003027A1 (fr)
EC (1) ECSP12012317A (fr)
GT (1) GT201200293A (fr)
IL (1) IL222534A0 (fr)
MA (1) MA34263B1 (fr)
MX (1) MX2012012615A (fr)
PE (1) PE20130213A1 (fr)
RU (1) RU2012151273A (fr)
SG (1) SG184458A1 (fr)
TN (1) TN2012000485A1 (fr)
TW (1) TW201142293A (fr)
WO (1) WO2011137206A1 (fr)
ZA (1) ZA201207481B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2600901B1 (fr) 2010-08-06 2019-03-27 ModernaTX, Inc. Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
HRP20220796T1 (hr) 2010-10-01 2022-10-14 ModernaTX, Inc. Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe
WO2012084873A1 (fr) * 2010-12-20 2012-06-28 Novartis Ag Esters d'acides 4-(hétéro)aryl-éthynyl-octahydro-indole-1-carboxyliques
CA2831613A1 (fr) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Administration et formulation d'acides nucleiques genetiquement modifies
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (fr) 2011-10-03 2020-03-04 ModernaTX, Inc. Nucléosides, nucléotides et acides nucléiques modifiés et leurs utilisations
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
WO2013131981A1 (fr) 2012-03-08 2013-09-12 Novartis Ag Marqueurs de prédiction utiles dans le diagnostic et le traitement du syndrome de l'x fragile (fxs)
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151664A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014152600A2 (fr) * 2013-03-15 2014-09-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesure des taux de fmrp cellulaire pour le criblage d'un médicament à haut rendement et diagnostic du syndrome du x fragile
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
CA2926645C (fr) 2013-10-14 2022-10-25 Indiana University Research And Technology Corporation Utilisation d'acamprosate pour moduler l'activation d'erk 1/2 dans des modeles animaux pour sxf et tsa et individus chez lesquels on a diagnostique le sxf et le tsa
CN103981253A (zh) * 2014-03-27 2014-08-13 江苏佰龄全基因生物医学技术有限公司 一种用于检测脆性x染色体综合征的cgg重复数及agg插入信息的pcr试剂盒
EP4244631A1 (fr) * 2020-11-13 2023-09-20 Children's Hospital Medical Center Utilisations affinées de modulateurs du récepteur gabaa dans le traitement du syndrome de l'x fragile

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6143504A (en) * 1998-10-27 2000-11-07 Arch Development Corporation Methods and compositions for the diagnosis of fragile X syndrome
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
WO2004014881A2 (fr) 2002-08-09 2004-02-19 Astra Zeneca Ab Nouveaux composes
JP4453297B2 (ja) 2003-05-27 2010-04-21 トヨタ自動車株式会社 車両用遊星歯車式多段変速機
TW200801005A (en) 2005-08-15 2008-01-01 Astrazeneca Ab Acetylenic piperazines as metabotropic glutamate receptor antagonists
US20090042195A1 (en) * 2005-10-07 2009-02-12 Bradford Coffee Methods and systems for screening for and diagnosing dna methylation associated abnormalities and sex chromosome aneuploidies
US7855053B2 (en) * 2006-07-19 2010-12-21 The Regents Of The University Of California Methods for detecting the presence of expanded CGG repeats in the FMR1 gene 5′ untranslated region
US20110136146A1 (en) 2008-08-04 2011-06-09 Novartis Ag Bioassay for polyq protein
US20100248239A1 (en) * 2009-03-24 2010-09-30 Mayo Foundation For Medical Education And Research Methods and materials for detecting fragile x mutations

Also Published As

Publication number Publication date
US20130052644A1 (en) 2013-02-28
TN2012000485A1 (en) 2014-04-01
ECSP12012317A (es) 2013-01-31
JP2013524840A (ja) 2013-06-20
GT201200293A (es) 2014-06-09
PE20130213A1 (es) 2013-03-19
ZA201207481B (en) 2013-06-26
EP2563934A1 (fr) 2013-03-06
BR112012027816A2 (pt) 2017-08-08
AU2011245372A1 (en) 2012-11-29
WO2011137206A1 (fr) 2011-11-03
CN102869791A (zh) 2013-01-09
CL2012003027A1 (es) 2014-02-14
KR20130100906A (ko) 2013-09-12
TW201142293A (en) 2011-12-01
SG184458A1 (en) 2012-11-29
CA2797854A1 (fr) 2011-11-03
IL222534A0 (en) 2012-12-31
MX2012012615A (es) 2012-12-17
RU2012151273A (ru) 2014-06-10

Similar Documents

Publication Publication Date Title
MA34263B1 (fr) Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)
MA38632B1 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
EA201490265A1 (ru) Ингибиторы тирозинкиназы брутона
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
MA35660B1 (fr) Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
ATE552262T1 (de) Spiroketone als inhibitoren von acetyl-coa- carboxylase
EA201300239A1 (ru) Антитела к fap и способы их применения
BRPI0913119A2 (pt) Inibidores de sinalização de proteína wnt
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
MA35395B1 (fr) Biomarqueurs pour une therapie par inhibiteur de hedgehog
EA201291477A1 (ru) КОМБИНАЦИЯ СОЕДИНЕНИЙ GlyT1 С АНТИПСИХОТИЧЕСКИМИ СРЕДСТВАМИ
MA38500A1 (fr) Systèmes et procédés pour analyser une nourriture pour animal
EA201490832A1 (ru) Биомаркеры, имеющие прогностическое значение в отношении ответа на лечение активатором альфа 7 никотиновых ацетилхолиновых рецепторов
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
AT10541U2 (de) Vorrichtung zur bestimmung der konzentration von feststoffpartikeln
EA201391627A1 (ru) Анализ на наличие лизилоксидазоподобных белков 2 и способы его применения
FR2929946B1 (fr) Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
EA201171178A1 (ru) Устройство и способ для определения и количественного анализа аналитов, в частности, микотоксинов
EA201401201A1 (ru) Способ
MA34827B1 (fr) Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes
FR2993574B1 (fr) Marqueurs moleculaires et methodes pour l'identification precoce du sexe du palmier dattier
FR2902320B1 (fr) Utilisation de butylated hydroxyanisole pour le traitement de la canitie